Injured patient's identity a mystery after 1 week in Los Angeles hospital
The patient was brought to Los Angeles General Medical Center on March 19 but staff members have been unable to locate any friends or family that can identify him.
The man believed to be in his early to late 60s was found in the 2300 block of Pasadena Avenue with apparent facial trauma.
He was described as possibly Hispanic with a small cross tattoo on his left forearm and a small star tattoo on his left bicep.
The patient is 5 feet 5 inches tall and weighs about 120 pounds with salt and pepper-colored curly hair and dark brown eyes.
Anyone with information was asked to contact Clinical Social Worker Jonathan Evanculla at 323-409-3859 between 8 a.m. and 5 p.m. Monday through Thursday. Calls can also be directed to the L.A. General Medical Center Department of Social Work at 323-409-5253.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
9 hours ago
- New York Post
Three babies die amid ‘concerning rise' of syphilis in New York — what to know about the dangerous disease
At least three babies have died of presumed congenital syphilis in New York state this year, prompting health officials to warn about the risks of the preventable infection. A pregnant woman can pass syphilis, a sexually transmitted infection, to her fetus. Left untreated, congenital syphilis can lead to miscarriage, premature birth, skeletal abnormalities, neurological problems, developmental delays, stillbirth or infant death shortly after birth. 3 There's been a 'concerning rise' in congenital syphilis cases in New York this year, state health officials said this week. HENADZY – Advertisement 'Detecting syphilis early in pregnancy with a simple blood test is important to ensure rapid diagnosis and treatment, so you have a healthy baby,' State Health Commissioner Dr. James McDonald said in a statement this week. New York has reported 21 cases of congenital syphilis in counties outside of NYC this year. Authorities did not disclose where the three infant deaths happened, except that they weren't in the city. There were 36 cases in the region outside of NYC last year, including five stillbirths and one infant death. Eight infant deaths presumptively linked to syphilis were recorded in the area between 2019 and 2023. Advertisement 'The highest rates we're seeing are in Native Americans, American Indians, Alaska Natives, Hispanic populations and black populations,' Kristin Wall, an associate professor of epidemiology at Emory University's Rollins School of Public Health, told ABC News about national congenital syphilis trends. 'And I think it's really important to think about access to care barriers as one of the big reasons that we're seeing these increasing rates in certain populations.' 3 A newborn in 1963 displays signs of congenital syphilis. Getty Images Unsurprisingly, there has been a 'concerning' rise in infectious syphilis cases among female New York residents, contributing to a nationwide surge. Advertisement Researchers have speculated that the increase could be due to decreased condom use, a disruption in healthcare routines because of the COVID-19 pandemic, inadequate sex education and disparities in access to testing and screening services. New York officials observed that substance use and hepatitis C were notable threads throughout congenital syphilis cases in the state. Last year, New York implemented a requirement for syphilis screening during the third trimester. Advertisement Pregnant women must now be tested for syphilis at their first prenatal appointment, in their third trimester (between weeks 28 and 32) and at delivery. Penicillin is the recommended treatment for syphilis, though some people may be allergic. In those cases, desensitization may be necessary. Unfortunately, there's been a nationwide penicillin shortage for months, compounding syphilis concerns. 3 A syphilis rash often appears as reddish-brown spots on the palms of the hands and soles of the feet. Stock Media Labs – Syphilis is spread by vaginal, anal or oral sex. Symptoms typically emerge 10 to 90 days after exposure, starting with a painless sore that appears at the site where the bacterium Treponema pallidum entered the body. The sore can heal on its own in three to six weeks, even as the infection persists. In the next stage of infection, symptoms can include a rash, fever, fatigue, sore throat, swollen lymph nodes and hair loss. Advertisement Syphilis is typically diagnosed with a blood test. New York's health department reminded residents that they have access to at-home testing options for sexually transmitted infections. If not addressed, syphilis can devastate the brain, heart and nervous system, leading to blindness, paralysis and even death.
Business Upturn
14 hours ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Wire
15 hours ago
- Business Wire
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Aspirina, the #1 pain relief option in Mexico 1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. Bayer's Aspirina, the #1 pain relief option in Mexico, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. Share As the Hispanic population in the U.S. continues to grow, currently representing 19 percent of the population and projected to reach 28 percent by 2060, Bayer Aspirin recognizes the importance of connecting with this vibrant community. The Aspirina pain relief option resonates deeply with cultural values and family traditions of those from Mexican and Latin American descent who have been using it as a long-standing pain relief option. 'Many Hispanic communities still face inadequate access to healthcare and consumer goods. As the fastest-growing demographic group in the U.S., the Hispanic population presents a unique opportunity for Bayer. By adding Aspirina to the U.S. portfolio, which has a strong equity in LATAM, we are placing the consumer at the center of our strategy. Data shows that 70 percent of Hispanic consumers feel a strong connection to their country of origin, making it essential for brands to honor and reflect this sentiment,' said Mohamed Atef, Global Brand Lead for Aspirin at Bayer. Many U.S. consumers of Hispanic origin grew up with Bayer's Aspirina— their parents and grandparents relied on it, instilling trust and nostalgia for the brand. Due to those deep connections, Aspirina has a 99 percent awareness rate in Mexico, with 67 percent of consumers using it regularly 2. With this inclusion in the U.S. market, we invite consumers to reconnect with a product that represents reliability, familiarity and their heritage. Bayer invented modern aspirin 125 years ago, and it's the most trusted aspirin brand for pain relief in the U.S. 3 Many pain reliever brands have come and gone over the last century, but Bayer® Aspirin continues to be one of the most trusted pain brands on the market. Aspirina is available at select Walmart and Walgreens, making it easy for families to find the pain relief they know. Join us in celebrating the launch of Aspirina in the U.S. and rediscover a brand that feels like home — a trusted companion in the journey of life. For more information on Aspirina visit About Aspirina For over 125 years, Bayer® Aspirin has been a leading aspirin brand in proven pain relief. Aspirina is a powerful pain reliever and fever reducer that contains 500 mg of the active ingredient aspirin (NSAID*). It provides fast and effective multi-symptom relief of headaches, muscle pain, toothaches, menstrual pain and minor arthritis pain for adults and children over 12, when used as directed. Aspirina is coated to make it easy to swallow and is free of caffeine. *nonsteroidal anti-inflammatory drug About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Based on volume sales in the last 52 weeks, via source: Grupo Knoblock/CID – Centro Integrador de Datos
